A Comparison of B Cell-Targeting Treatments for Multiple Sclerosis
DOI:
https://doi.org/10.58445/rars.1598Keywords:
Multiple Sclerosis, B cell, Targeted Treatment, Clinical TrialsAbstract
Multiple sclerosis (MS) is the most common chronic inflammatory neurodegenerative disease in young adults and a leading cause of nontraumatic neurological disability. The cause of MS is not fully understood, but both genetic and environmental factors are believed to play a role. B cells are an important part of the immune response and have been shown to play a significant role in MS. This paper reviews studies on various B cell-targeting treatments for MS to determine which are the most effective at specific stages of the disease. In the end, all of the treatments that were investigated were found to be effective for treating relapsing-remitting MS, and results varied for primary progressive and secondary progressive MS.
References
Hauser, S. L., & Cree, B. A. C. (2020). Treatment of multiple sclerosis: A Review. The American Journal of Medicine, 133(12). https://doi.org/10.1016/j.amjmed.2020.05.049
Walton, C., King, R., Rechtman, L., Kaye, W., Leray, E., Marrie, R. A., Robertson, N., La Rocca, N., Uitdehaag, B., van der Mei, I., Wallin, M., Helme, A., Angood Napier, C., Rijke, N., & Baneke, P. (2020). Rising prevalence of multiple sclerosis worldwide: Insights from the atlas of MS, Third edition. Multiple Sclerosis Journal, 26(14), 1816–1821. https://doi.org/10.1177/1352458520970841
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021). Diagnosis and treatment of multiple sclerosis. JAMA, 325(8), 765. https://doi.org/10.1001/jama.2020.26858
Murphy, K., Janeway, C. Alderson, Travers, P., & Walport, M. Jeremy. (2012). Janeway's immunobiology. 8th ed. New York: Garland Science.
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A., & Muraro, P. A. (2021). B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies. Nature Reviews Neurology, 17(7), 399–414. https://doi.org/10.1038/s41582-021-00498-5
Comi, G., Bar‐Or, A., Lassmann, H., Uccelli, A., Hartung, H., Montalban, X., Sørensen, P. S., Hohlfeld, R., & Hauser, S. L. (2020). Role of B cells in multiple sclerosis and related disorders. Annals of Neurology, 89(1), 13–23. https://doi.org/10.1002/ana.25927
Fraussen, J., Claes, N., de Bock, L., & Somers, V. (2014). Targets of the humoral autoimmune response in multiple sclerosis. Autoimmunity Reviews, 13(11), 1126–1137. https://doi.org/10.1016/j.autrev.2014.07.002
Filippini, G., Kruja, J., & Del Giovane, C. (2021). Rituximab for people with multiple sclerosis. Cochrane Database of Systematic Reviews, 2021(11). https://doi.org/10.1002/14651858.cd013874.pub2
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., Langer-Gould, A., & Smith, C. H. (2008). B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. New England Journal of Medicine, 358(7), 676–688. https://doi.org/10.1056/nejmoa0706383
Hawker, K., O’Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., Zhang, J., Chin, P., & Smith, C. H. (2009). Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial. Annals of Neurology, 66(4), 460–471. https://doi.org/10.1002/ana.21867
Florou, D., Katsara, M., Feehan, J., Dardiotis, E., & Apostolopoulos, V. (2020). Anti-CD20 agents for multiple sclerosis: Spotlight on ocrelizumab and ofatumumab. Brain Sciences, 10(10), 758. https://doi.org/10.3390/brainsci10100758
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., Traboulsee, A., Wolinsky, J. S., Arnold, D. L., Klingelschmitt, G., Masterman, D., Fontoura, P., Belachew, S., Chin, P., Mairon, N., … Kappos, L. (2017). Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine, 376(3), 221–234. https://doi.org/10.1056/nejmoa1601277
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Rammohan, K. W., Selmaj, K., Traboulsee, A., Sauter, A., Masterman, D., Fontoura, P., Belachew, S., Garren, H., … Wolinsky, J. S. (2017). Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine, 376(3), 209–220. https://doi.org/10.1056/nejmoa1606468
Bar-Or, A., Grove, R. A., Austin, D. J., Tolson, J. M., VanMeter, S. A., Lewis, E. W., Derosier, F. J., Lopez, M. C., Kavanagh, S. T., Miller, A. E., & Sorensen, P. S. (2018). Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis. Neurology, 90(20). https://doi.org/10.1212/wnl.0000000000005516
Hauser, S. L., Bar-Or, A., Cohen, J. A., Comi, G., Correale, J., Coyle, P. K., Cross, A. H., de Seze, J., Leppert, D., Montalban, X., Selmaj, K., Wiendl, H., Kerloeguen, C., Willi, R., Li, B., Kakarieka, A., Tomic, D., Goodyear, A., Pingili, R., … Kappos, L. (2020). Ofatumumab versus teriflunomide in multiple sclerosis. New England Journal of Medicine, 383(6), 546–557. https://doi.org/10.1056/nejmoa1917246
Krämer, J., Bar-Or, A., Turner, T. J., & Wiendl, H. (2023). Bruton tyrosine kinase inhibitors for multiple sclerosis. Nature Reviews Neurology, 19(5), 289–304. https://doi.org/10.1038/s41582-023-00800-7
Montalban, X., Arnold, D. L., Weber, M. S., Staikov, I., Piasecka-Stryczynska, K., Willmer, J., Martin, E. C., Dangond, F., Syed, S., & Wolinsky, J. S. (2019). Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. New England Journal of Medicine, 380(25), 2406–2417. https://doi.org/10.1056/nejmoa1901981
Reich, D. S., Arnold, D. L., Vermersch, P., Bar-Or, A., Fox, R. J., Matta, A., Turner, T., Wallström, E., Zhang, X., Mareš, M., Khabirov, F. A., Traboulsee, A., Grand’Maison, F., Jacques, F., Traboulsee, A., Tyblova, M., Meluzinova, E., Ampapa, R., Valis, M., … Robertson, D. (2021). Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: A phase 2B, randomised, double-blind, placebo-controlled trial. The Lancet Neurology, 20(9), 729–738. https://doi.org/10.1016/s1474-4422(21)00237-4
Downloads
Posted
Categories
License
Copyright (c) 2024 Ryan Verma
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.